Summary & Overview
HCPCS Level II Q4297: Emerge Matrix, Per Square Centimeter
Headline: HCPCS Level II code Q4297 covers Emerge matrix billed per square centimeter as an add-on for wound and surgical procedures.
Lead: HCPCS Level II code Q4297 designates the Emerge matrix product and is billed per square centimeter as an add-on to a primary procedure. This code matters nationally because it standardizes reporting and reimbursement for an adjunctive wound matrix product commonly used in complex wound management and reconstructive procedures.
Overview: The code represents an implantable or adjunctive wound matrix measured by area and appended to a primary wound care or surgical service. It enables more granular accounting of product use and costs in settings such as hospital outpatient departments, ambulatory surgical centers, and specialty wound clinics. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides benchmarks and utilization context for add-on matrix products billed per square centimeter, summaries of payer coverage approaches, clinical contexts where the product is applied, and policy considerations affecting coding and billing for adjunctive wound matrices. Data limitations and unspecified items are noted as "Data not available in the input."
Billing Code Overview
HCPCS Level II code Q4297 describes Emerge matrix, per square centimeter (add-on, list separately in addition to primary procedure). This code represents billing for a biologic or skin substitute matrix product measured and billed by the square centimeter when used in conjunction with a primary wound care or surgical procedure.
Service Type: Implantable/adjunctive wound matrix product
Typical Site of Service: Hospital outpatient departments, ambulatory surgical centers, wound care clinics, and other procedural settings where the primary wound or surgical procedure is performed.
Clinical & Coding Specifications
Clinical Context
A patient presents with a full-thickness or deep partial-thickness wound requiring advanced wound matrix coverage to promote granulation and re-epithelialization. Typical scenarios include chronic non-healing diabetic foot ulcers, pressure ulcers with exposed subcutaneous tissue, large traumatic soft tissue defects after debridement, or complex surgical wounds where native tissue closure is not possible. Wounds are assessed by a wound care specialist or surgeon in an outpatient wound clinic, hospital wound service, or ambulatory surgery center. After sharp debridement and control of infection, the clinician selects an extracellular matrix product such as an Emerge matrix. The product is measured in square centimeters and applied to the wound bed as an adjunct to standard wound care. The procedure is billed as an add-on supply per square centimeter (Q4297) in addition to a primary procedure for debridement, incision and drainage, local wound care, or reconstructive procedure. Typical sites of service include outpatient wound care clinics, hospital outpatient departments, ambulatory surgery centers, and inpatient hospital settings when used as part of surgical wound management. Patient workflow includes wound assessment, documentation of size and viability, informed consent for use of biologic matrix, application of the matrix in a sterile field, dressing application, and scheduled follow-up visits for dressing changes and wound monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |